[Reactivity differences between serums of patients infected with HIV-2 and HIV-1 antigens according to the patients' geographic origin].
Identifieur interne : 000C38 ( Ncbi/Merge ); précédent : 000C37; suivant : 000C39[Reactivity differences between serums of patients infected with HIV-2 and HIV-1 antigens according to the patients' geographic origin].
Auteurs : F. Simon [France] ; I. Loussert-Ajaka ; G. Collin ; E. Gamba ; A. Powell-Smith ; S. Gadelle ; F. Brun-VézinetSource :
- Sante (Montrouge, France) [ 1157-5999 ]
Descripteurs français
- KwdFr :
- Afrique (ethnologie), Antigènes du VIH (immunologie), Dosage par radioimmunoprécipitation, France (épidémiologie), Humains, Infections à VIH (immunologie), Infections à VIH (sang), Infections à VIH (épidémiologie), Mali (épidémiologie), Réactions croisées, Surveillance de la population, Technique de Western, Techniques immunoenzymatiques, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie), VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (immunologie), Études séroépidémiologiques.
- MESH :
- ethnologie : Afrique.
- immunologie : Antigènes du VIH, Infections à VIH, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), VIH-2 (Virus de l'Immunodéficience Humaine de type 2).
- sang : Infections à VIH.
- épidémiologie : France, Infections à VIH, Mali.
- Dosage par radioimmunoprécipitation, Humains, Réactions croisées, Surveillance de la population, Technique de Western, Techniques immunoenzymatiques, Études séroépidémiologiques.
- Wicri :
English descriptors
- KwdEn :
- Africa (ethnology), Blotting, Western, Cross Reactions, France (epidemiology), HIV Antigens (immunology), HIV Infections (blood), HIV Infections (epidemiology), HIV Infections (immunology), HIV-1 (immunology), HIV-2 (immunology), Humans, Immunoenzyme Techniques, Mali (epidemiology), Population Surveillance, Radioimmunoprecipitation Assay, Seroepidemiologic Studies.
- MESH :
- chemical , immunology : HIV Antigens.
- geographic , epidemiology : France, Mali.
- geographic , ethnology : Africa.
- blood : HIV Infections.
- epidemiology : HIV Infections.
- immunology : HIV Infections, HIV-1, HIV-2.
- Blotting, Western, Cross Reactions, Humans, Immunoenzyme Techniques, Population Surveillance, Radioimmunoprecipitation Assay, Seroepidemiologic Studies.
Abstract
We tested 98 sera from HIV-2-infected patients for cross-reactivity with HIV-1 antigens in a competitive EIA test and western blotting. The sera were obtained during epidemiological surveys in Cape Verde Islands (n = 47) and Mali (n = 51). There were significantly more cross reactions with sera from Mali. Similar results were obtained with sera from African patients resident in France. Samples from HIV-2-infected patients from Burkina Faso, Ghana, Ivory Coast and Mali were more often reactive with HIV-1 antigens than were those from HIV-2-infected patients from the western Atlantic coast (Cape Verde, Guinea Bissau and Senegal). These data underline the importance of using specific tests for HIV-2 sero-positivity, and the need to include a panel of HIV-2-positive sera of different geographic origins in quality control kits.
PubMed: 8162361
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000802
- to stream PubMed, to step Curation: 000802
- to stream PubMed, to step Checkpoint: 000802
Links to Exploration step
pubmed:8162361Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Reactivity differences between serums of patients infected with HIV-2 and HIV-1 antigens according to the patients' geographic origin].</title><author><name sortKey="Simon, F" sort="Simon, F" uniqKey="Simon F" first="F" last="Simon">F. Simon</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de virologie, Hôpital Bichat-Claude Bernard, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de virologie, Hôpital Bichat-Claude Bernard, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Loussert Ajaka, I" sort="Loussert Ajaka, I" uniqKey="Loussert Ajaka I" first="I" last="Loussert-Ajaka">I. Loussert-Ajaka</name></author><author><name sortKey="Collin, G" sort="Collin, G" uniqKey="Collin G" first="G" last="Collin">G. Collin</name></author><author><name sortKey="Gamba, E" sort="Gamba, E" uniqKey="Gamba E" first="E" last="Gamba">E. Gamba</name></author><author><name sortKey="Powell Smith, A" sort="Powell Smith, A" uniqKey="Powell Smith A" first="A" last="Powell-Smith">A. Powell-Smith</name></author><author><name sortKey="Gadelle, S" sort="Gadelle, S" uniqKey="Gadelle S" first="S" last="Gadelle">S. Gadelle</name></author><author><name sortKey="Brun Vezinet, F" sort="Brun Vezinet, F" uniqKey="Brun Vezinet F" first="F" last="Brun-Vézinet">F. Brun-Vézinet</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>1994 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:8162361</idno><idno type="pmid">8162361</idno><idno type="wicri:Area/PubMed/Corpus">000802</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000802</idno><idno type="wicri:Area/PubMed/Curation">000802</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000802</idno><idno type="wicri:Area/PubMed/Checkpoint">000802</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000802</idno><idno type="wicri:Area/Ncbi/Merge">000C38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Reactivity differences between serums of patients infected with HIV-2 and HIV-1 antigens according to the patients' geographic origin].</title><author><name sortKey="Simon, F" sort="Simon, F" uniqKey="Simon F" first="F" last="Simon">F. Simon</name><affiliation wicri:level="3"><nlm:affiliation>Laboratoire de virologie, Hôpital Bichat-Claude Bernard, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Laboratoire de virologie, Hôpital Bichat-Claude Bernard, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Loussert Ajaka, I" sort="Loussert Ajaka, I" uniqKey="Loussert Ajaka I" first="I" last="Loussert-Ajaka">I. Loussert-Ajaka</name></author><author><name sortKey="Collin, G" sort="Collin, G" uniqKey="Collin G" first="G" last="Collin">G. Collin</name></author><author><name sortKey="Gamba, E" sort="Gamba, E" uniqKey="Gamba E" first="E" last="Gamba">E. Gamba</name></author><author><name sortKey="Powell Smith, A" sort="Powell Smith, A" uniqKey="Powell Smith A" first="A" last="Powell-Smith">A. Powell-Smith</name></author><author><name sortKey="Gadelle, S" sort="Gadelle, S" uniqKey="Gadelle S" first="S" last="Gadelle">S. Gadelle</name></author><author><name sortKey="Brun Vezinet, F" sort="Brun Vezinet, F" uniqKey="Brun Vezinet F" first="F" last="Brun-Vézinet">F. Brun-Vézinet</name></author></analytic><series><title level="j">Sante (Montrouge, France)</title><idno type="ISSN">1157-5999</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Africa (ethnology)</term><term>Blotting, Western</term><term>Cross Reactions</term><term>France (epidemiology)</term><term>HIV Antigens (immunology)</term><term>HIV Infections (blood)</term><term>HIV Infections (epidemiology)</term><term>HIV Infections (immunology)</term><term>HIV-1 (immunology)</term><term>HIV-2 (immunology)</term><term>Humans</term><term>Immunoenzyme Techniques</term><term>Mali (epidemiology)</term><term>Population Surveillance</term><term>Radioimmunoprecipitation Assay</term><term>Seroepidemiologic Studies</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Afrique (ethnologie)</term><term>Antigènes du VIH (immunologie)</term><term>Dosage par radioimmunoprécipitation</term><term>France (épidémiologie)</term><term>Humains</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (sang)</term><term>Infections à VIH (épidémiologie)</term><term>Mali (épidémiologie)</term><term>Réactions croisées</term><term>Surveillance de la population</term><term>Technique de Western</term><term>Techniques immunoenzymatiques</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (immunologie)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2) (immunologie)</term><term>Études séroépidémiologiques</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>HIV Antigens</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term><term>Mali</term></keywords><keywords scheme="MESH" type="geographic" qualifier="ethnology" xml:lang="en"><term>Africa</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="ethnologie" xml:lang="fr"><term>Afrique</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes du VIH</term><term>Infections à VIH</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>VIH-2 (Virus de l'Immunodéficience Humaine de type 2)</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>HIV Infections</term><term>HIV-1</term><term>HIV-2</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>France</term><term>Infections à VIH</term><term>Mali</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Blotting, Western</term><term>Cross Reactions</term><term>Humans</term><term>Immunoenzyme Techniques</term><term>Population Surveillance</term><term>Radioimmunoprecipitation Assay</term><term>Seroepidemiologic Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Dosage par radioimmunoprécipitation</term><term>Humains</term><term>Réactions croisées</term><term>Surveillance de la population</term><term>Technique de Western</term><term>Techniques immunoenzymatiques</term><term>Études séroépidémiologiques</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term><term>Mali</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We tested 98 sera from HIV-2-infected patients for cross-reactivity with HIV-1 antigens in a competitive EIA test and western blotting. The sera were obtained during epidemiological surveys in Cape Verde Islands (n = 47) and Mali (n = 51). There were significantly more cross reactions with sera from Mali. Similar results were obtained with sera from African patients resident in France. Samples from HIV-2-infected patients from Burkina Faso, Ghana, Ivory Coast and Mali were more often reactive with HIV-1 antigens than were those from HIV-2-infected patients from the western Atlantic coast (Cape Verde, Guinea Bissau and Senegal). These data underline the importance of using specific tests for HIV-2 sero-positivity, and the need to include a panel of HIV-2-positive sera of different geographic origins in quality control kits.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8162361</PMID><DateCreated><Year>1994</Year><Month>05</Month><Day>20</Day></DateCreated><DateCompleted><Year>1994</Year><Month>05</Month><Day>20</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1157-5999</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>1</Issue><PubDate><MedlineDate>1994 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Sante (Montrouge, France)</Title><ISOAbbreviation>Sante</ISOAbbreviation></Journal><ArticleTitle>[Reactivity differences between serums of patients infected with HIV-2 and HIV-1 antigens according to the patients' geographic origin].</ArticleTitle><Pagination><MedlinePgn>27-31</MedlinePgn></Pagination><Abstract><AbstractText>We tested 98 sera from HIV-2-infected patients for cross-reactivity with HIV-1 antigens in a competitive EIA test and western blotting. The sera were obtained during epidemiological surveys in Cape Verde Islands (n = 47) and Mali (n = 51). There were significantly more cross reactions with sera from Mali. Similar results were obtained with sera from African patients resident in France. Samples from HIV-2-infected patients from Burkina Faso, Ghana, Ivory Coast and Mali were more often reactive with HIV-1 antigens than were those from HIV-2-infected patients from the western Atlantic coast (Cape Verde, Guinea Bissau and Senegal). These data underline the importance of using specific tests for HIV-2 sero-positivity, and the need to include a panel of HIV-2-positive sera of different geographic origins in quality control kits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratoire de virologie, Hôpital Bichat-Claude Bernard, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loussert-Ajaka</LastName><ForeName>I</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Collin</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gamba</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Powell-Smith</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gadelle</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Brun-Vézinet</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Différence de réactivité des sérums de patients infectés par le VIH-2 sur les antigénes VIH-1 en fonction de leur origine géographique.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Sante</MedlineTA><NlmUniqueID>9212437</NlmUniqueID><ISSNLinking>1157-5999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015488">HIV Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000349" MajorTopicYN="N" Type="Geographic">Africa</DescriptorName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015153" MajorTopicYN="N">Blotting, Western</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015488" MajorTopicYN="N">HIV Antigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="Y">HIV-1</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015498" MajorTopicYN="Y">HIV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007124" MajorTopicYN="N">Immunoenzyme Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008302" MajorTopicYN="N" Type="Geographic">Mali</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011159" MajorTopicYN="Y">Population Surveillance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015531" MajorTopicYN="N">Radioimmunoprecipitation Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8162361</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Île-de-France</li></region><settlement><li>Paris</li></settlement></list><tree><noCountry><name sortKey="Brun Vezinet, F" sort="Brun Vezinet, F" uniqKey="Brun Vezinet F" first="F" last="Brun-Vézinet">F. Brun-Vézinet</name><name sortKey="Collin, G" sort="Collin, G" uniqKey="Collin G" first="G" last="Collin">G. Collin</name><name sortKey="Gadelle, S" sort="Gadelle, S" uniqKey="Gadelle S" first="S" last="Gadelle">S. Gadelle</name><name sortKey="Gamba, E" sort="Gamba, E" uniqKey="Gamba E" first="E" last="Gamba">E. Gamba</name><name sortKey="Loussert Ajaka, I" sort="Loussert Ajaka, I" uniqKey="Loussert Ajaka I" first="I" last="Loussert-Ajaka">I. Loussert-Ajaka</name><name sortKey="Powell Smith, A" sort="Powell Smith, A" uniqKey="Powell Smith A" first="A" last="Powell-Smith">A. Powell-Smith</name></noCountry><country name="France"><region name="Île-de-France"><name sortKey="Simon, F" sort="Simon, F" uniqKey="Simon F" first="F" last="Simon">F. Simon</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000C38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:8162361
|texte= [Reactivity differences between serums of patients infected with HIV-2 and HIV-1 antigens according to the patients' geographic origin].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8162361" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |